Topic: Onglyza
Drug makers Bristol-Myers Squibb Co. and AstraZeneca PLC said Friday that they received U.S. marketing approval for a once-a-day diabetes drug that combines the starter diabetes drug metformin with the companies' newer drug Onglyza.. Bristol-Myers and AstraZeneca are partners on Onglyza, which ...
Onglyza is a drug which is prescribed for type 2 diabetes which is non-insulin dependent diabetes. It cannot be prescribed for anyone with type 1 diabetes whose pancreas makes virtually no insulin. The purpose of Onglyza is to get your body to ...
Drugmaker Bristol-Myers expected to focus on new drug approvals, more on horizon in 3Q reportBristol-Myers Squibb Co., the maker of popular blood thinners Plavix and Coumadin, is likely to spend some time trumpeting its latest acquisition, plus two recent drug approvals and ...
Bristol-Myers expected to focus on drug research progress, approval prospects in 2Q reportDrugmaker Bristol-Myers Squibb Co. is expected to focus on a raft of recent positive research data and plans to seek approval for several drugs when it reports its second-quarter results ...
PRINCETON, N.J. & Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and ...
Recently, Bristol-Myers Squibb Company (BMY) and AstraZeneca Plc (AZN) announced that the U.S. Food and Drug Administration [FDA] has accepted their application for reviewing the combination of a fixed dose of Onglyza (saxagliptin) and metformin for treating patients suffering from type II ...
On Friday, Bristol-Myers Squibb Co. (BMY) announced that its diabetes drug dapagliflozin, in combination with metformin (commonly prescribed oral anti-diabetic medication), significantly reduced levels of glycosylated haemoglobin which is an indication of glucose concentration in the blood in type II diabetes patients ...
Doctors, paramedics and other health-care workers in Indiana, Illinois and Tennessee were the first Americans to receive the H1N1 swine flu vaccine as the U.S. government commenced its nationwide immunization effort Monday.. Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak ...
PRINCETON, N.J. and Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZAT (saxagliptin) 5 mg per day achieved the primary objective of ...
Onglyza (saxagliptin) has been approved by the U.S. Food and Drug Administration to treat type 2 diabetes in adults, the agency said Friday.. While there's no evidence of increased risk of cardiovascular problems among Onglyza users, the agency said it ordered a ...
